Quantum Biopharma Ltd. (QNTM) Quantum BioPharma Ltd., a biopharmaceutical firm headquartered in Toronto, Canada, is dedicated to the discovery and advancement of biotechnological solutions and drug candidates. The company focuses on addressing complex neurodegenerative, inflammatory, and metabolic conditions, alongside alcohol use disorder, with its pipeline featuring a range of drug candidates at varying stages of development. Its operations are divided into two main divisions: its core biopharmaceutical activities and strategic investment holdings. A flagship asset is Lucid-MS, a novel, proprietary chemical entity currently in Phase 2 clinical trials. Preclinical data indicates its potential to prevent and reverse the degradation of myelin, a key process underlying multiple sclerosis. Furthermore, Quantum BioPharma is developing a therapeutic solution for alcohol addiction, intended for application in hospital and clinical environments. The company's strategic investments portfolio includes various loans collateralized by residential real estate. Previously known as FSD Pharma Inc., the company adopted its current name, Quantum BioPharma Ltd., in August 2024.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Quantum BioPharma Ltd. NASDAQ:QNTM Healthcare · Biotechnology
Mkt Cap $19.25M
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release ⚠ 2
Quantum BioPharma Signs Contract with Thermo Fisher Scientific’s Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis
Quantum BioPharma signed a Study Start-Up Agreement with Thermo Fisher Scientific's clinical research business to implement its Phase 2 trial of Lucid-MS in multiple sclerosis.
The milestone follows FDA clearance to proceed, moving the program from regulatory clearance into formal study start-up with a CRO experienced in CNS and MS trials.
The randomized, double-blind, placebo-controlled Phase 2 study will evaluate efficacy, safety and tolerability of Lucid-MS in progressive forms of MS using clinical and radiological endpoints.
• 26d ago AI analysis › Press Release
IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd.
Quantum BioPharma's Executive Co-Chair Anthony Durkacz appeared on The BioMedWire Podcast to discuss the company's lead drug candidate Lucid-MS, which is advancing to a Phase 2 trial in multiple sclerosis patients targeting myelin repair.
Durkacz also highlighted unbuzzd™, the alcohol-metabolism powder spun out to Unbuzzd Wellness Inc., which is currently going through an IPO process ahead of a planned full marketing launch.
Quantum owns approximately 19.48% of Unbuzzd (as of June 30, 2026) and holds a 7% royalty on sales until payments total $250 million, dropping to 3% thereafter. The release is promotional investor-content distribution, not new company disclosure.
• 1mo ago AI analysis › Press Release ⚠ 4
Quantum Biopharma Licensee Unbuzzd Wellness to Advance Clinically Validated Alcohol Metabolism Accelerant After Appointing Zappy as CEO
Quantum BioPharma's licensee Unbuzzd Wellness appointed Michael "Zappy" Zapolin as CEO, with a mandate to finance and list the company on a stock exchange and execute a nationwide US rollout of the unbuzzd alcohol-metabolism beverage.
Quantum BioPharma retains 19.48% ownership of Unbuzzd and a 7% royalty on sales until payments total $250 million, after which the royalty drops to 3% in perpetuity.
The release also cites a peer-reviewed clinical trial showing BAC reduction more than 40% faster within 30 minutes and a 67% reduction in headache severity at four hours; unbuzzd is sold as a dietary supplement on Amazon and unbuzzd.com.
• 1mo ago AI analysis › Press Release ⚠ 2
Rodman & Renshaw Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$8 Price Target
Rodman & Renshaw has initiated research coverage of Quantum BioPharma (NASDAQ: QNTM) with a BUY rating and a US$8 price target, led by senior biotechnology analyst Michael G. King Jr.
The coverage is unpaid — the release stresses the company paid no fees and provided no consideration for the report, which lends credibility to the call.
Quantum is a micro-cap biopharma whose lead compound Lucid-MS is still preclinical in multiple sclerosis; it also holds 19.48% of Unbuzzd Wellness plus a 7% royalty on unbuzzd sales until payments reach $250 million, then 3% in perpetuity.
An initiation can improve visibility for a thinly covered name and may precede a banking relationship, but the price target ultimately rests on early-stage assets.
• 1mo ago AI analysis › Press Release
Quantum BioPharma to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto
Quantum BioPharma will present at the 3rd Annual ArcStone-Kingswood Growth Summit in Toronto on September 16, 2026, with co-founder and Executive Co-chairman Anthony Durkacz covering recent milestones and the company's growth strategy.
The summit brings together growth issuers with institutional investors, family offices, and capital-markets professionals for a day of presentations, panels, and curated 1-on-1 meetings.
The release contains no new financial, clinical, or regulatory data; it restates the company's positioning, including lead compound Lucid-MS for multiple sclerosis and a 19.48% stake in Unbuzzd alongside 7% royalties on sales until payments reach $250 million.
This is a routine investor-relations event with no measurable near-term fundamental impact on the company.
• 1mo ago AI analysis › Press Release ⚠ 3
NetworkNewsAudio Announces Audio Press Release (APR) Discussing FDA Clearance for Trial of First-in-Class Treatment Creating ‘Rare Moment’ in MS Research
The FDA has cleared Quantum BioPharma's Investigational New Drug application for Lucid-MS, allowing the micro-cap biotech to move directly into a randomized, double-blind, placebo-controlled Phase 2 trial in multiple sclerosis.
The IND submission ran approximately 15,000 pages of pharmacology, toxicology and manufacturing data, and Lucid-MS -- the lead compound of subsidiary Lucid Psycheceuticals -- has so far shown it can prevent and reverse myelin degradation only in preclinical models.
Note this is a third-party promotional audio release from NetworkNewsAudio/IBN rather than an issuer disclosure, so the underlying clearance should be verified against Quantum's own filings.
• 1mo ago AI analysis › Press Release ⚠ 4
Quantum BioPharma Ltd. (NASDAQ: QNTM) Filling Key Gap in MS Treatment, Cleared by FDA to Launch Historic Trials
Quantum BioPharma says the FDA has cleared it to launch a Phase 2 trial of Lucid-MS, a patented, first-in-class candidate designed to shield and potentially rebuild the myelin sheath in multiple sclerosis rather than suppress the immune system.
The editorial frames the clearance as the first time this mechanism would be tested in MS patients and claims it has already drawn a fresh buy rating from Wall Street analysts, though no analyst or firm is named.
Notably, this is a BioMedWire/IBN editorial placement distributed through GlobeNewswire, not an issuer-authored disclosure; the milestone should be confirmed in Quantum's own filings or press releases before trading on it.
Background from the release: Quantum retains 19.84% of spinout Unbuzzd Wellness and earns 7% royalties on unbuzzd sales until payments to Quantum total $250 million, after which the royalty drops to 3% in perpetuity.
• 1mo ago AI analysis › Press Release ⚠ 4
Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
Bristol-Myers Squibb is not the subject of this release: it is a GlobeNewswire-distributed BioMedWire sponsored editorial profiling Quantum BioPharma's FDA clearance to run a Phase 2 trial of Lucid-MS, a first-in-class PAD2 inhibitor designed to protect and potentially rebuild myelin in multiple sclerosis.
BMY appears only in the closing roundup of industry developments, which recaps previously released positive Phase 2 results for arlocabtagene autoleucel (arlo-cel) in quadruple-class exposed relapsed/refractory multiple myeloma from the QUINTESSENTIAL trial.
The editorial cites a global MS therapeutics market projected at roughly $38.62 billion by 2030 and QNTM analyst targets of $8 (Rodman & Renshaw) and $45 (Kingswood, September 2025), none of which pertain to BMY.
Treat this as low-signal promotional content for BMY watchers; the piece contains no new issuer disclosure about Bristol-Myers Squibb.
• 1mo ago AI analysis › Press Release ⚠ 4
Quantum BioPharma Ltd. NASDAQ: QNTM) Receives FDA Clearance to Begin Trials for Historic MS Treatment
Quantum BioPharma has received FDA clearance to begin a Phase 2 trial of Lucid-MS, its patented, first-in-class candidate designed to protect and potentially repair the myelin sheath damaged in multiple sclerosis.
The clearance would make this the first time a drug candidate built on this mechanism is tested in people living with MS, a milestone the release says has already drawn a fresh buy rating from Wall Street analysts. Nearly one million people in the U.S. and about 2.9 million worldwide live with the disease.
Caveat for agents: this item is a third-party editorial placement distributed by BioMedWire/IBN, not a company-issued release — the buy rating is unattributed and the underlying clearance should be verified against issuer filings.
• 1mo ago AI analysis › Press Release ⚠ 4
A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach
BioMedWire, an IBN paid communications platform, published a promotional editorial on GlobeNewswire whose real subject is Quantum BioPharma (QNTM), not the filer Biogen. The piece centers on FDA clearance of Quantum's IND to run a randomized, double-blind, placebo-controlled Phase 2 trial of Lucid-MS (Lucid-21-302), a first-in-class PAD2 inhibitor designed to protect and repair myelin rather than suppress the immune system.
Biogen's only substantive appearance is a recap that China's NMPA approved the subcutaneous formulation of LEQEMBI as an initiation treatment for early Alzheimer's disease, following Priority Review after a January 2026 acceptance. No new Biogen disclosure, financial figure, or guidance appears anywhere in the article.
The editorial also cites a Rodman & Renshaw Buy initiation with an $8 price target on QNTM, an earlier unpaid $45 target from Kingswood Capital Partners, an MGH/Harvard PET imaging collaboration using the [18F]3F4AP tracer, and a projected $38.62 billion MS therapeutics market by 2030.
For BIIB holders this is third-party marketing noise with peripheral relevance; the lone BIIB-adjacent item (LEQEMBI China approval) is a previously reported recap embedded in paid promotional content.
• 1mo ago AI analysis › Press Release ⚠ 1
Quantum BioPharma Announces Plans to Voluntarily Delist its Class B Shares from the Canadian Securities Exchange
Quantum BioPharma has applied to voluntarily delist its Class B subordinate voting shares from the Canadian Securities Exchange while maintaining its listings on the Nasdaq Capital Market, Frankfurt Stock Exchange, and Upstream.
Management stated that trading volume on the CSE no longer justified the associated expenses and regulatory burdens, and they believe consolidating trading to Nasdaq may benefit long-term liquidity.
The last trading day on the CSE is expected to be September 4, 2026, subject to approval, though the company will remain a reporting issuer in Canada and continue filing on SEDAR+.
• 2mo ago AI analysis › Press Release
Quantum Biopharma Provides Corporate Update
Quantum BioPharma granted 572,500 stock options to directors, officers, and consultants, exercisable at C$4.80 for a five-year term expiring in August 2031.
172,500 of the options vested immediately, while the remaining 400,000 are subject to performance-based vesting conditions under the company's omnibus equity incentive plan.
• 2mo ago AI analysis › Press Release ● Major ⚠ 3
Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial
Quantum BioPharma received FDA clearance to advance its lead asset Lucid-MS into a pivotal Phase 2 clinical trial for progressive multiple sclerosis.
The company reported a strengthened balance sheet for Q2, with combined cash and digital assets rising to $9.5 million and total operating expenses dropping 53% year-over-year.
Management confirmed that the current liquidity profile is sufficient to fund planned operations through at least October 2027.
• 2mo ago AI analysis › Press Release ● Major ⚠ 2
Quantum BioPharma Receives United States FDA Clearance To Proceed with Lucid-MS Phase 2 Trial in Progressive Multiple Sclerosis:
Quantum BioPharma secured FDA clearance to proceed with a Phase 2 clinical trial of Lucid-MS for progressive multiple sclerosis, validating its IND application for this first-in-class neuroprotective therapy.
The randomized, double-blind, placebo-controlled study targets the underlying mechanism of demyelination, addressing a market projected to reach $38.62 billion globally by 2030.
The company reported over $10 million in cash, digital assets, and liquid investments as of March 31, 2026, to support its clinical development runway.
• 2mo ago AI analysis › Press Release
Quantum BioPharma Announces Closing of Debt Settlement
Quantum BioPharma closed the settlement of CAD$123,487.43 owed to arm's-length creditors and insiders through the issuance of Class B subordinate voting shares.
The company issued an aggregate of 30,948 shares at a deemed price of CAD$3.99 per share, representing the closing price on the CSE prior to the transaction closing.
Securities issued in this settlement have not been registered under the U.S. Securities Act and are not intended for distribution in the United States.
• 3mo ago AI analysis › Press Release ⚠ 1
Quantum BioPharma Announces Intention to Settle Debt
Quantum BioPharma's board approved the settlement of CAD$123,487.43 owed to creditors and insiders through the issuance of Class B subordinate voting shares.
The issuance price will be based on the lower of CAD$4.26 or the closing price of the Class B Shares on the Canadian Securities Exchange prior to the closing date.
The securities issued have not been registered under the U.S. Securities Act and will not be offered or sold in the United States.
• 3mo ago AI analysis › Press Release ⚠ 1
Quantum BioPharma Provides Corporate Update
Quantum BioPharma retained FinnCom, Inc. for a six-month contract to provide marketing and investor awareness services starting June 24, 2026.
The total cash consideration for the agreement is USD 170,500, consisting of a USD 20,500 initiation payment and six monthly installments of USD 25,000.
FinnCom, an arm's-length firm based in California, does not hold any securities in Quantum BioPharma according to the company's disclosure.
• 3mo ago AI analysis › Press Release
NetworkNewsAudio Announces Audio Press Release (APR) the Advancement of First-in-Class Treatment for Multiple Sclerosis
NetworkNewsAudio released an audio press release featuring Quantum BioPharma, highlighting the development of its Lucid-MS drug candidate for multiple sclerosis.
The content describes Lucid-MS as a first-in-class therapy targeting the myelin sheath, designed to prevent, stop, or reverse degradation based on preclinical models.
The release also notes Quantum's retained 19.84% ownership in Unbuzzd Wellness Inc. and details a royalty structure that declines from 7% to 3% after $250 million in payments.
• 4mo ago AI analysis › Press Release ⚠ 2
Quantum BioPharma Ltd. (NASDAQ: QNTM) Advancing Innovative, First-in-Class, Patented MS Therapy
Quantum BioPharma announced its placement in a BioMedWire editorial highlighting its lead asset, Lucid-MS, a patented therapy for Multiple Sclerosis.
The company states that Lucid-MS is preparing to move into Phase 2 clinical trials, targeting the myelin sheath to prevent and reverse disease-related degradation.
Additionally, Quantum retains a 19.84% ownership stake in Unbuzzd Wellness Inc., along with royalty rights that start at 7% of sales until a $250 million cap is reached.
• 4mo ago AI analysis › Press Release ⚠ 2
The Quest to Repair What Multiple Sclerosis Takes Away
Bristol Myers Squibb announced that the European Commission has approved Opdivo (nivolumab) in combination with doxorubicin, vinblastine and dacarbazine for adult and adolescent patients with previously untreated stage 3 or 4 classical Hodgkin lymphoma.
This approval establishes the Opdivo plus AVD regimen as the first immunotherapy-based treatment available in the European Union for newly diagnosed advanced cHL.
• 4mo ago AI analysis › Press Release ⚠ 2
Quantum BioPharma Ltd. (NASDAQ: QNTM) Developing Patented, First-in-Class MS Treatment That Offers Different Approach
Quantum BioPharma announced that its lead drug candidate Lucid-MS is preparing to enter Phase 2 clinical trials, targeting the myelin sheath to treat multiple sclerosis.
The company retains a 19.84% ownership stake in Unbuzzd Wellness Inc., a spinout entity, and is entitled to a 7% royalty on sales until total payments reach $250 million, after which the rate drops to 3% in perpetuity.
The announcement was made through a featured editorial noting that more than 2.9 million people worldwide currently live with MS.
• 4mo ago AI analysis › Press Release ● Major
Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
Biogen is expanding its immunology pipeline through a definitive agreement to acquire RayThera Inc. for up to $1 billion. The deal structure consists of an upfront payment alongside payments contingent on future clinical and regulatory milestones.
The acquisition will add multiple anti-inflammatory assets to Biogen's portfolio, including a lead asset poised to enter Phase 1 development. These assets target immune-mediated conditions across a range of indications.
• 4mo ago AI analysis › Press Release ⚠ 2
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd.
Quantum BioPharma (QNTM) announced the release of a new BioMedWire Podcast episode featuring Executive Co-Chair Anthony Durkacz, distributed by third-party firm IBN.
Durkacz reiterated the company's focus on its lead multiple sclerosis candidate, Lucid-MS, noting that an IND has been filed for a Phase 2 trial in MS patients, which will be the first time the drug is tested in humans with the disease.
He also discussed the commercial asset unbuzzd, an alcohol metabolism product sold via Amazon, and confirmed Quantum retains a 19.84% stake in the spun-out entity Unbuzzd Wellness Inc., along with a 7% royalty on sales until $250 million is reached.
• 4mo ago AI analysis › Press Release
Quantum BioPharma Engages Stocks.news For Investor Relations, Marketing Services And Lead Generation Campaigns
Quantum BioPharma has entered into a six-month agreement with IR Agency LLC (operating through Stocks.news) for investor relations and marketing services.
The company will pay a fee of US$250,000 for the engagement, which begins on June 8, 2026.
The release includes standard boilerplate descriptions of the company's pipeline, including its lead compound Lucid-MS for multiple sclerosis and its royalty arrangement with spin-out Unbuzzd Wellness.
• 4mo ago AI analysis › Press Release ● Major ⚠ 3
Quantum BioPharma Provides Corporate Update
The FDA placed a clinical hold on Quantum BioPharma’s IND for Lucid-MS, its lead multiple sclerosis candidate, pending submission of additional information.
The company withdrew all previously disclosed timelines for Phase 2 trial initiation and interim data milestones, citing the need to address the agency’s comments.
Dr. Lakshmi P. Kotra resigned as a director effective June 1, 2026, though he will remain as a senior clinical advisor.
• 5mo ago AI analysis › Press Release
Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital
Quantum BioPharma reached the halfway enrollment milestone in its collaborative imaging study with Massachusetts General Hospital, reporting encouraging preliminary results.
The study validates a novel PET tracer, [¹⁸F]3F4AP, which can directly assess demyelinated neurons with intact axons in multiple sclerosis patients, offering a potential biomarker for tracking disease progression and treatment response.
This imaging platform supports the development of Quantum’s lead asset, Lucid-MS, for which an IND submission for a Phase 2 trial was filed with the FDA in March 2026.
• 5mo ago AI analysis › Press Release
Quantum Reports Strengthened Liquidity, Reduced Cash Burn, and Disciplined Cost Management in First Quarter 2026
Quantum BioPharma reported Q1 2026 results showing a strengthened balance sheet, with total cash and digital assets rising to $11.2 million and cash burn dropping 60% year-over-year to $1.66 million.
Operationally, the company submitted an IND application for its MS drug candidate Lucid-MS, appointed a principal investigator, and signed a binding LOI with Allucent to manage the planned Phase 2 trial.
Additionally, a U.S. District Court ruled in Quantum's favor regarding its lawsuit against CIBC and RBC, denying the banks' motion to dismiss claims of market manipulation.
• 5mo ago AI analysis › Press Release ⚠ 3
Quantum BioPharma Provides Corporate Update
Quantum BioPharma retained the services of Senergy Communications Capital and King Tide Media for marketing and investor awareness on one-month contracts beginning in May.
The agreements, which include options for renewal, will cost the company a total of $275,000 covering service fees and advertising initiatives.
The company continues to focus on its lead compound Lucid-MS for multiple sclerosis and holds a 19.84% stake in Unbuzzd Wellness, maker of the unbuzzd product.
• 6mo ago AI analysis › Press Release ⚠ 2
Quantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accelerant
Unbuzzd Wellness Inc., a 19.84%-owned licensee of Quantum BioPharma, appointed Richard Buzbuzian as CEO to lead the nationwide commercialization of the hangover remedy unbuzzd.
The subsidiary plans to launch sales in South Florida and Texas, targeting a functional beverage market projected to reach $198 billion in 2026.
Quantum BioPharma retains a 7% royalty on unbuzzd sales until payments reach $250 million, positioning the parent company to benefit from the product's commercial execution.
• 6mo ago AI analysis › 
